Revelation Biosciences, Inc. (NASDAQ:REVB) Short Interest Down 31.1% in February

Revelation Biosciences, Inc. (NASDAQ:REVB) saw a significant decrease in short interest in the month of February. As of February 28th, there was short interest totalling 61,700 shares, a decrease of 31.1% from the February 13th total of 89,500 shares. Based on an average trading volume of 214,800 shares, the short-interest ratio is currently 0.3 days. Currently, 6.8% of the shares of the stock are short sold.

Revelation Biosciences Stock Down 29.1 %

Shares of Revelation Biosciences stock traded down $0.99 during trading hours on Monday, reaching $2.41. 1,842,168 shares of the company’s stock were exchanged, compared to its average volume of 111,327. Revelation Biosciences has a 1 year low of $2.38 and a 1 year high of $60.80. The company has a market capitalization of $645,880.00, a P/E ratio of -0.01 and a beta of 0.17. The business has a fifty day moving average of $4.94 and a two-hundred day moving average of $9.40.

Revelation Biosciences Company Profile

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.